Rensselaer Polytechnic Institute (RPI) has been awarded two grants by the National Institute on Aging (NIA) to train graduate students on Alzheimer’s disease (AD) research and commercialization. NIA is one of the National Institutes of Health in the U.S. Department of Health and Human Services and is the primary federal agency supporting and conducting AD research.
Presented by Rensselaer Polytechnic Institute, Storytelling and Memory will be performed by the Tanglewood Music Center’s Fromm Quartet at the Curtis R. Priem Experimental Music and Performing Arts Center (EMPAC) at Rensselaer on Friday, August 2 at 7 p.m. Free admission is available by registering at https://webforms.rpi.edu/storytelling-memory-tanglewood-music-center.
Chunyu Wang, M.D., Ph.D., professor of biological sciences and chemistry and chemical biology at Rensselaer Polytechnic Institute, has been awarded a five-year grant of more than $3.7 million by the National Institutes of Health’s National Institute on Aging to study Apolipoprotein E (ApoE) isoform interactions with heparan sulfate (HS) in Alzheimer’s disease (AD).
Rensselaer Polytechnic Institute’s Boleslaw Szymanski, Ph.D., and Chunyu Wang, M.D. Ph.D., have been elected fellows of the American Association for the Advancement Science (AAAS). Steven Cramer, Ph.D., who was elected AAAS Fellow in 2017, was elected Council Member of the Section on Engineering.
An antioxidant found in green tea may increase levels of p53, a natural anti-cancer protein, known as the “guardian of the genome” for its ability to repair DNA damage or destroy cancerous cells.
A new grant from the National Institute On Aging at the National Institutes of Health will support ongoing research at Rensselaer Polytechnic Institute to address Alzheimer’s disease caused by gene mutations. According to Chunyu Wang, the principal investigator and an assistant professor of biological sciences at Rensselaer, the project seeks to understand and counter the mechanism that produces Amyloid-Beta 42 peptide in brain cells.
Armed with evidence that a specific site on heparan sulfate — known as the 3-O-sulfate group — is critical to the transfer of harmful tau proteins in the brain, a research program funded by the NIH’s National Institute of Aging is scrutinizing the interactions between heparan sulfate and tau, determining how misfolded tau spreads in the brain, and developing strategies to block it.
A newly identified compound is a promising candidate for inhibiting the production of amyloids, the abnormal proteins that form toxic clumps, called fibrils, inside the brains of patients with Alzheimer’s disease. As published in the Royal Society of Chemistry’s Chemical Communications, the compound — known as “C1” — uses a novel mechanism to efficiently prevent the enzyme gamma-secretase from producing amyloids.
With support from the Warren Alpert Foundation, researchers at Rensselaer Polytechnic Institute have launched a search for drug candidates to block a biological process associated with Alzheimer’s disease.